Central Venous Catheter Associated Infections Pathophysiology, Incidence, Clinical Diagnosis, and Prevention - A Review

The incidence of catheter related bloodstream infections poses a substantial burden on patient’s life’s and well‐being. Estimated 2 – 6 % of patients suffer from catheter associated bloodstream infections (BSI). Reports on mortality of these patients are up to 30 % in addition to a substantial prolongation of hospital days. The estimated cost of therapy of a BSI is approximately 10 000 € per patient. There is a definitive need for antimicrobially active medical devices for prophylaxis. Endowment of catheters with antibiotics and desinfectants have substantial limitations regarding spectrum of activity, duration of activity and clinical efficacy. The oligodynamic activity of silver has the greatest potential for prevention of catheter related infections. Various technologies in particular surface coating of these medical devices have been advocated previously with limited success. A new technology with impregnation of the entire catheter matrix with billions of nanoparticles of silver0 which results in a surface of 2000 cm2/g polyurethane (PU) has been developed. Central venous catheters manufactured according to the technology of the first and second generation have been investigated with good results of antimicrobial activity and biocompatibility. Favorable results in experimental investigations and good clinical results in controlled prospective, randomized, investigator blinded studies of the first generation silver catheter have been obtained. In 660 patients in an overall reduction of BSI of 66 % was observed. Favorable results in a postmarketing surveillance with 3000 patients were seen. The premarketing surveillance of the second generation silver‐catheter indicated an even greater reduction of catheter related BSI. In 204 patients with a mean duration of catheter placement of 9.2 days only one catheter related BSI was diagnosed. The rate of catheter colonization was